Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cellsSangya Agarwal, Carl H. June, M. Ángela Aznar et al.|Immunity|2023Cited by 164
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer modelsPatrizia Porazzi, Marco Ruella, Linhui Chen et al.|Cancer Cell|2025Cited by 47
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P. Patel, Patrizia Porazzi, Guido Ghilardi et al.|Science Immunology|2024Cited by 45
The BTLA–HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Marco Ruella, Alberto Carturan et al.|Nature Immunology|2024Cited by 41
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Marco Ruella, Luca Paruzzo et al.|Blood Advances|2023Cited by 30